KRAS mutations reduce the efficacy of erlotinib, as evidenced in patients with non-small-cell lung cancer where KRAS mutations led to diminished progression-free survival with erlotinib plus chemotherapy [69]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.